C&G companies are opening the door to a paradigm shift in medicine. They are developing some of the most exciting new therapeutics that we have seen for decades and they are doing it quickly, delivering meaningful results for patients that are changing lives for the better.

However, C&G companies face a unique set of challenges which set them apart from the rest of the sector. They are subject to short time-frames, putting company leaders under high pressure from day one and creating the need for an alternative, faster growth strategy dependent on people and money. Management teams need to be built faster and be more broadly-based than in purely R&D focused drug discovery enterprises. Nick and Mark talk about the profiles of the people at the heart of these companies and how they’re assembled into winning teams that evolve and flex over time according to the funding available and pipeline needs.

For more information visit The RSA Group website on www.thersagroup.com and to keep up to date with latest reports and industry insights check out its LinkedIn Page and Twitter Page.